Implantable prosthetic valve

Information

  • Patent Grant
  • 7267686
  • Patent Number
    7,267,686
  • Date Filed
    Wednesday, November 10, 2004
    20 years ago
  • Date Issued
    Tuesday, September 11, 2007
    17 years ago
Abstract
A prosthetic valve for implantation within a fluid conducting lumen within a body includes an elongate generally cylindrical radially collapsible valve body scaffold defining a fluid passageway therethrough for retentive positioning within the lumen. A radially collapsible leaf valve member is supported by the scaffold includes a number of valve leafs deflectable between a closed position restricting fluid flow through the passageway and an open position permitting fluid flow through the passageway. The leaf valve member includes an interior leaf valve frame defining a valve leaf aperture which is sealed by a fluid impermeable non-thrombogenic lining to prevent fluid flow therethrough.
Description
FIELD OF THE INVENTION

The present invention relates to the field of implantable prostheses. More specifically, the present invention relates to implantable prosthetic cardiac, aortic, and venous valves.


BACKGROUND OF THE INVENTION

In human pathology, the proper functioning of both cardiac and venous valves is of paramount importance. Disorders of cardiac valves cause significant morbidity and mortality. These disorders affect persons of all ages and can result from congenital or degenerative conditions, as well as from the sequelae of infections. Stenosis and insufficiency of the aortic or mitral valves have a greater incidence than stenosis and insufficiency of the tricuspid and pulmonary valves. Venous insufficiency is believed to contribute to various maladies, including edema, varicose veins, aching leg pain while standing, lipodermatosclerosis, and ulcerations. Venous insufficiency is essentially caused by venous hypertension and chronic venous stasis due to valvular incompetence both of an idiopathic nature and of a secondary nature following past illnesses of the venous systems.


A prosthetic cardiac or venous valve may regulate the direction of the pulsating blood flow so as to limit the occurrence of blood stasis in the region about the valve. By maintaining the direction of blood flow therethrough, a prosthetic cardia, aortic, or venous valve may alleviate the maladies resulting from valve disorders or venous insufficiency. A prosthetic valve should therefore permit blood flow in the proper predetermined direction to limit or prevent backflow of the blood in a reverse direction.


The art has seen several attempts for providing a prosthetic valve to alleviate the consequences of cardiac valve disorders and of venous insufficiency. These attempts generally fall into two categories, biologic valves and mechanical valves. Biologic valves are comprised of a stent supporting a number of circumferential leaflets made of a flexible material. If the material is biologic in nature, it may be either a xenograft, that is, harvested from a non-human cadaver, or an allograft, that is, harvested from a human cadaver. For example, it is known in the art to apply a pericardium biological tissue layer covering, for providing the valve leaflets, to a stent which provides structural annular integrity to the prosthesis. Non-biologic material such as polyurethane has also been used. The second category of prosthetic valves, mechanical valves, usually comprise a rigid annulus supporting up to three rigid leaflets. The annulus and leaflets are frequently formed in pyrolitic carbon, a particularly hard and wear resistant form of carbon. The annulus is captured within a sewing ring so that the valve may be attached to tissue at the location of the replaced valve. Unfortunately, surgically positioning these implants typically requires suturing or sewing the device into the blood vessel, increasing the risk of thrombosis due to the resulting suturing or anastomoses of the body vessel.


These attempts typically provide a valve structure having a relatively rigid tubular body structure which supports a flexible valve leaf structure. That is, any structural rigidity imparted to the tubular body structure is separated from the valve leaf structure. For example, U.S. Pat. No. 4,759,759 discloses a prosthetic valve having a solid stent member having a diametrically-opposed upstanding posts and a substantially cylindrical flexible cover. The two portions of the cover extending between the upstanding stent posts may be collapsed against each other in sealing registry over a fluid passageway defined by the stent. The stent, being a solid member, limits the radial collapsing thereof for endoscopic delivery within a body lumen. The cover, being unsupported by the stent within the fluid passageway of the valve, must itself provide sufficient strength and resiliency to optimally regulate fluid flow. Alternatively, U.S. Pat. No. 5,855,691 discloses a prosthetic valve having a radially expandable covered stent which defines an elongate fluid passageway therethrough. A flexible valve is disposed within the fluid passageway to regulate fluid flow therethrough. The valve is formed of a flexible and compressible material formed into a disc with at least three radial incisions to form deflectable leaflets. While the stent circumferentially supports the valve body, the leaflets are not supported by any other structure within the fluid passageway. There is therefore a need in the art for a unitary prosthetic valve construction which provides structural reinforcement to both the tubular body portion of the valve and to the valve leafs supported thereon.


SUMMARY OF THE INVENTION

The present invention is directed to providing a fully prosthetic valve having valve leafs formed from a covered valve leaf frame and which may be implanted using a minimally-invasive, endoscopic technique.


The present invention provides a prosthetic valve for implantation within a body lumen. The prosthetic valve of the present invention provides a device for regulating and maintaining the direction of a pulsating fluid flow through the body lumen. The valve includes a radially-collapsible scaffold portion and a radially-collapsible leaf valve portion. The scaffold portion includes a tubular open body scaffold defining a fluid passageway therethrough. The leaf valve portion is deflectable between a closed configuration in which fluid flow through the valve passageway is restricted and an open configuration in which fluid flow through the valve passageway is permitted.


Each of the valve leafs desirably includes a valve leaf frame having an open construction so as to facilitate radially-collapsing or -expanding the leaf valve portion of the valve. Each valve leaf frame defines a valve leaf aperture with the scaffold. The present invention seals each valve leaf aperture to prevent fluid flow therethrough. The material used to seal each valve leaf aperture is sufficiently thin and pliable so as to permit radially-collapsing the leaf valve portion for delivery by catheter to a location within a body lumen. A fluid-impermeable biocompatible non-thrombogenic valve leaf cover may be positioned on each valve leaf frame so as to seal the valve leaf aperture. The valve leaf cover may be formed from a surgically-useful textile such as Dacron, polyethlylene (PE), polyethylene terephthalate (PET), silk, Rayon, or the like. The valve leaf cover may also be formed of a surgically-useful polymeric material such as urethane, polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE). The valve leaf cover may also coated with a cellular growth-inhibiting drug such as Heparin or Taxol or another such composition.


Similarly, each of the valve leaf apertures may be covered with cultured tissue cells derived from a either a donor or the host patient which are attached to the valve leaf frames. The cultured tissue cells may be initially positioned to extend either partially or fully into each valve leaf aperture. In order to provide additional support to the attached cultured tissue cells, a microfilter-type support mesh spanning the valve leaf aperture may also be provided. The present invention further contemplates that the supporting scaffold and valve leaf frames may be formed of either a bioabsorbable material or a non-bioabsorbable material. It is contemplated that the scaffold and valve leaf frames which are formed from a bioabsorbable material will eventually be displaced by the tissue cells as the tissue cells mature. Eventually the cells alone will provide the fully functioning valve. Alternatively, when the scaffold and valve leaf frames are formed from a non-bioabsorbable material, the cultured cells provide a means for reducing any undesirable biological response by the host.


The leaf valve member is normally spring biased towards the closed configuration. The present invention also contemplates biasing the leaf valve member towards the open configuration to simulate known anatomical mechanics of a valve in which the leaf valve portion would close upon experiencing sufficient back flow pressure from the direction downstream from the valve.


The leaf valve portion desirably includes a number of valve leafs which are deflected between the closed and open configurations when the fluid pressure differential thereacross exceeds a predetermined threshold. That is, the fluid pressure differential acts to open the valve when the fluid pressure upstream of the valve leaf portion is greater than the fluid pressure downstream of the valve leaf portion.


Each of the valve leafs is deflectably supported by the scaffold at a flexible hinge. The present invention contemplates that the open and closed configurations of the valve may be defined either downstream or upstream of the flexible hinges. It is desired that the scaffold portion of the valve will eventually provide fluid-tight engagement with the body lumen although it is contemplated that some leaking or fluid flow between the scaffold portion and the body lumen is still acceptable. Just as it is preferred, but not required, that the valve leafs prevent fluid flow in the closed configuration, it is recognized that substantial restriction of fluid flow past the scaffold-lumen interface may still provide a prosthetic valve exhibiting acceptable performance characteristics.


The present invention shows and describes both a bicuspid valve and a six-leaf valve, although designs employing a different number of valve leafs are clearly within the scope of the present invention. The bicuspid valve includes a pair of leaf frames which deflect about a hinge positioned downstream of the closable valve opening. The six-leaf variant includes valve leafs which deflect about hinges positioned upstream of the closable valve opening.


The abutting engagement between adjacent valve leafs, while desirably providing a fluid-tight seal, is contemplated to significantly restrict backflow past the valve leafs. The abutting engagement between adjacent valve leafs may therefore provide less than complete fluid integrity while still achieving the desired performance parameters.


The scaffold of the valve includes a first end defining a first opening, a second end defining a second opening, a substantially cylindrical interior face, a substantially cylindrical exterior face, and at least one radially-extending scaffold opening communicating between interior and exterior faces. The interior face generally defines the fluid passageway. The scaffold and leaf valve member are formed to be expandable from a first diameter permitting delivery through the body lumen to a second radially-expanded diameter for retentively engaging the body lumen at a desired location. The scaffold may be formed having a shape memory favoring radial self-expansion or may be formed so as to permit radial expansion by a delivery balloon which is deflated and withdrawn after scaffold expansion against the body lumen. The scaffold may further provide at least one radially outwardly projecting hook member for retentively engaging the fluid conduit when expanded thereagainst.


The present invention also contemplates forming both the scaffold and the valve leaf frames as a unitary support trellis. The unitary trellis may be formed by a single undulating wire bent to form both the radially expandable scaffold portion and the radially expandable valve leaf frames. While various configurations for the unitary support trellis of the present invention are contemplated, one preferred configuration bends a wire along a longitudinally extending and retracting undulating path so as to alternately define a collapsible and expandable leaf frame aperture and then a collapsible and expandable scaffold aperture. The wire may be laid along a flat surface so as to form a planar trellis preform. The trellis preform may then be wrapped about an elongate cylindrical mandrel. The valve leaf frames may be deflected about their respective hinges to establish a shape memory in either the open or closed configuration either prior to or after wrapping the trellis preform about the mandrel.


The trellis is desirably formed from a biocompatible metal or polymeric material. The trellis may additionally be formed from a shape-memory material to more reliably provide the required geometry to function effectively within the valve once radially expanded at a site within a lumen. The trellis may be formed from an alloy of nickel and titanium in specific proportions known in the art as nitinol. Alternatively, the trellis may be formed from a polymeric material which allows the trellis to be radially collapsed for delivery to a site in a lumen but then radially expands to return to an undeflected shape so as to function effectively within the valve.


The present invention also contemplates attaching an elongate generally cylindrical first biocompatible non-thrombogenic liner to the trellis. The first liner may be positioned on either the interior or exterior face of the scaffold. The first liner may also provide the sealing cover for the valve leaf frame apertures. The first liner may be trimmed to span between adjacent valve leafs in the open configuration so as to provide a larger surface area for the body fluid to act upon when urging the valve leafs between the open and closed configuration. The first liner may also be trimmed to provide at least one flap extending in the downstream direction beyond each valve leaf. Each flap may then be folded over the adjacent valve leaf frame and laminated through a valve leaf aperture to the liner.


Furthermore, an elongate generally cylindrical second biocompatible non-thrombogenic liner may be positioned on the scaffold opposite the first liner. The second liner may desirably extend only along a portion of the scaffold or fully along scaffold. The first and second liners may be joined so as to fully encase either just the scaffold or the entire trellis. It is contemplated that the first and second liners may be laminated together through one or more openings defined by the trellis. Additionally, the second liner may be formed by folding the first liner over the first end of the scaffold so as to extend at least partially along the opposite face of the scaffold as the first lining.


Each liner positioned on the trellis may inhibit thrombus formation and facilitate tissue ingrowth therethrough for assimilating the valve of the present invention into the body lumen. Towards this latter goal, one or both of the liners may be formed from a porous textile or polymeric material. It is further contemplated that either liner may be formed from an xenograft of cellular tissue from a donor such as bovine cardial tissue, or homograft of cellular tissue formed from the host patient.


It is also contemplated by the present invention that the prosthetic valve may also be attached to the interior surface of a second radially collapsible prosthetic fluid conduit. The second fluid conduit may be selected from many known stent and covered stent designs known in the art. The second fluid conduit further maintains the patency of the lumen to either side of the valve and may also include a biocompatible fluid impermeable non-thrombogenic lining on either or both of its own inner or outer surfaces. The materials used to form the second fluid conduit may also be selected to be either bioabsorbable or non-bioabsorbable as may be desired.


The present invention is also directed to methods of making the prosthetic valve of the present invention.


While the present invention has been described generally, the present invention will be more readily appreciated in a reading of the “Detailed Description of the Invention” with reference to the following drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows side elevational view of a prosthetic venous valve of the present invention in a closed, flow restricting configuration.



FIG. 2 shows a top elevational view of the prosthetic venous valve of FIG. 1 in the closed configuration.



FIG. 3 shows a side elevational view of the prosthetic venous valve of FIG. 1 in an open, flow conducting configuration.



FIG. 4 shows a top elevational view of the prosthetic venous valve of FIG. 1 in the open configuration.



FIG. 5 shows the unitary support trellis of the prosthetic venous valve of FIG. 1.



FIG. 6 shows a front elevational view of the unitary support trellis of the present invention in a flat trellis preform configuration.



FIG. 7 is a side elevational view of the unitary support scaffolding and valve leaflet frames upon being stressed to provide for a self-closing valve.



FIG. 8 depicts one step in a method of constructing the prosthetic valve of the present invention by wrapping the unitary support scaffolding and valve leaflet frames about a non-thrombogenic lining positioned about a mandrel.



FIG. 9 shows an isometric view of a unitary support trellis for a prosthetic valve of the present invention.



FIG. 10 shows a perspective view of a prosthetic valve of the present invention in an open configuration and in which the scaffold portion of the valve is substantially uncovered.



FIG. 11 shows a side elevational view of the prosthetic valve of FIG. 10.



FIG. 12 shows a side elevational view of the prosthetic valve of FIG. 10 in an open configuration.



FIGS. 13A-D depict a further embodiment of the present invention in which adjacent leaf frames are joined at a location therealong to reduce the size of the valve flow opening.



FIG. 14 shows an embodiment a prosthetic valve of the present invention in which a unitary support trellis is positioned over a liner.



FIG. 15 shows an alternate embodiment of a prosthetic valve of FIG. 14 in which a second liner is positioned on the trellis to extend across the proximal end of the scaffold portion.



FIG. 16 is a side elevational view of an alternate embodiment of a prosthetic valve of the present invention in an open, flow-conducting configuration in which a non-thrombogenic webbing spans between each adjacent leaflet of the valve.



FIG. 17 shows an alternate embodiment of the present invention in which a secondary support scaffolding is formed to the downstream side of the valve leaflets.



FIG. 18 shows a still further embodiment of the present invention in which a number of deflectable valve leafs are attached within the fluid-conducting passageway to a radially-expandable prosthetic support structure.



FIG. 19 is a partial cut-away of the embodiment of FIG. 10 depicting the valve leaflets in a closed, flow-restricting configuration.



FIG. 20 is a partial cut-away of the embodiment of FIG. 11 depicting the valve leafs in an open, flow-conducting configuration.



FIG. 21 depicts an alternate embodiment of a covered valve leaf of the present invention to be attached to a radially expandable outer conduit.



FIGS. 22 and 23 depict a prosthetic bicuspid valve of the prior art in the open and closed configurations, respectively.



FIGS. 24A-B are respective side and top elevational views of a prosthetic bicuspid valve of the present invention in the closed configuration.



FIGS. 25A-B are respective side and top elevational views of a prosthetic bicuspid valve of the present invention in the open configuration.



FIGS. 26A-B depict a unitary scaffold for the prosthetic bicuspid valve of FIG. 24 in the closed configuration.



FIG. 26C depicts the scaffold for the prosthetic bicuspid valve of FIG. 24 in the open configuration.



FIGS. 27A-B are respective side and top elevational views of another embodiment of the prosthetic bicuspid valve of FIG. 24, having a larger valve leaf and shallower valve cusp, in the closed configuration.



FIGS. 28A-B are respective side and top elevational views of the prosthetic bicuspid valve of FIG. 27A in the open configuration.



FIGS. 29A-B are side elevational views of the scaffold of the prosthetic bicuspid valve of FIG. 27A and FIG. 28A, respectively.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates generally to method and apparatus for providing a fluid flow check valve for a body lumen. A preferred embodiment of the present invention is particularly suitable for forming an endoluminal prosthetic valve for vascular applications. The prosthetic valve of the present invention regulates and maintains the direction of a pulsating fluid flow through a body lumen. The prosthetic valve of the present invention is configured to open and close in response to the fluid pressure differential across the valve. The valve includes a radially-collapsible scaffold portion and a radially-collapsible leaf valve portion which allows the valve to be delivered via catheter through the body lumen in which it will be emplaced. The scaffold portion includes a tubular open body scaffold defining a fluid passageway therethrough. The leaf valve portion is deflectable between a closed configuration in which fluid flow through the valve passageway is restricted and an open configuration in which fluid flow through the valve passageway is permitted.


The preferred embodiment of the prosthetic valve of the present invention is designed to be biased towards a closed, flow-restricting configuration. The valve opens when sufficient fluid pressure is applied to the leaflets from the upstream direction. Desirably the valve will open when the pressure differential across the leaflets reaches about 1-20 mm Hg. When the pressure differential is too low, the valve closes to prevent back flow. The valve desirably withstands up to about 100 mm Hg of back flow pressure. When the pressure differential from blood flowing the desired direction is removed, the valve returns to the closed configuration.


As will be described in further detail hereinbelow for the six-leaf variant of the present invention, the leaf valve portion is connected to the scaffold portion so that the valve leafs are deflectable about an annularly extending hinge line. The location of the hinge line along the length of the leaf valve portion influences the fluid pressure required to open and close the valve. In the closed configuration, the valve leaf portion substantially restricts fluid flow through the valve by providing a biocompatible impermeable non-thrombogenic covering. extending from the hinge line in registry with the passageway.


Referring now to the drawings, FIGS. 1-5 depict a prosthetic valve 10 of the present invention. Valve 10 provides a radially-collapsible trellis 24 having an open construction. Trellis 24 includes an elongate tubular body scaffold 30 supporting a number of deflectable valve leaf frames 52 deflectable about a hinge line 22. Each valve leaf frame 52 defines a leaf frame aperture 62 which is sealed by a valve cover 80 positioned on trellis 24. The remainder of trellis 24 may also be covered with one or more liners 82 and 88, or may be left uncovered altogether. The covered leaf frames 52 form the deflectable valve leafs 40 which 16 may be moved out of abutting engagement with each other so as to permit fluid flow through valve 10 in response to the fluid pressure upstream thereof.


Valve 10 is provided for implantation within the fluid passageway of a body lumen, such as for replacement of a cardial, arterial, or venous valve, to regulate the flow of a bodily fluid therethrough in a single direction. Valve 10 is constructed from biocompatible materials so as to minimize any adverse body reaction to the implantation of valve 10. Valve 10 includes an elongate tubular body portion 12 and a leaf valve portion 14. Valve 10 includes an upstream end 16, a downstream end 18, and an elongate fluid passageway 20 extending therebetween along a valve axis 1v. Leaf valve portion 14 is connected to body portion 12 to extend in overlying registry with passageway 20. Leaf valve portion 14 includes one or more valve leafs 40 which are deflectable with respect to body portion 12 about a hinge line 22 between a closed configuration, shown in FIGS. 1 and 2, restricting fluid flow through passageway 20, and an open configuration, shown in FIGS. 3 and 4, permitting fluid flow through passageway 20. As shown in FIGS. 13A-D, hinge line 22 may be alternatively formed along the length of valve portion 14 by joining adjacent valve leafs 40 at a midway location 22′. Locating hinge line 22 further downstream from body portion 12 increases the required higher fluid pressure differential to deflect the valve leafs to the open configuration.


Leaf valve portion 14 may provide any number of valve leafs 40. While six valve leafs are provided and discussed by reference to FIGS. 1-4, a bicuspid valve configuration is also contemplated and will be further discussed hereinbelow. Still referring to FIGS. 1-4, each of the valve leafs 40 are similarly-sized and -shaped and include opposed first and second major surfaces 42 and 44, respectively. Each first major surface 42 of a valve leaf 40 is oriented in facing opposition towards upstream end 16 of valve 10. Each of the valve leafs 40 provide a sawtooth perimetrical edge formed by a first and second leaf edge 46 and 48, respectively, which are positionable in abutting engagement with a leaf edge of an adjacent valve leaf 40 to define the closed configuration of valve 10. Similarly, as best shown in FIG. 4, the leaf edges 46 and 48 define a valve leaf opening 50 when in the open configuration. Valve leaf opening 50 is in fluid communication with passageway 20.


All of the valve leafs 40 are formed having a spring bias towards either the open or the closed configuration. When all of the valve leafs 40 are spring biased towards the closed configuration, the open configuration may be attained when the fluid pressure acting on the first major surfaces 42 of the valve leafs 40 overcomes both the fluid pressure acting on the second major surfaces 44 of the valve leafs 40 of valve 10 and any spring bias closing force imparted to the valve leafs 40 acting to close the valve leafs. Should the fluid pressure from the downstream end 28 of valve 10 become too great relative to the upstream fluid pressure, the valve leafs 40 will also be urged towards the closed configuration. Each valve leaf 40 desirably curves inward such that the second major surface 44 has a concave shape to better collect backflow and urge the valve leafs 40 towards the closed configuration. The prosthetic valve 10 of the present invention thereby provides a device for regulating and maintaining the direction of a pulsating fluid flow through the body lumen. While leaf valve portion 14 is normally spring biased towards the closed configuration, it is also contemplated, however, to bias leaf valve portion 14 towards the open configuration in order to simulate known anatomical mechanics of certain valves. Thus, when biased towards the open configuration, leaf valve portion 14 would close upon experiencing sufficient back flow pressure from the downstream end 28 of valve 10.



FIG. 5 shows the unitary support trellis 24 employed by valve 10. Trellis 24 may be formed from a material exhibiting shape memory characteristics or from a material which is readily expandable by a balloon catheter. Trellis 24 is generally an elongate tube being coaxial with valve axis 1v. Trellis 24 has opposed upstream and downstream ends 26 and 28. Upstream end 26 of trellis 24 is further defined by a radially collapsible body scaffold 30. Downstream end 28 of trellis 24 is further defined by a radially-collapsible leaf valve framework 32.


Trellis 24 may be formed from a wide variety of materials and in a wide variety of configurations. Radially-expandable endovascular stents known in the art provide useful basic designs for modification into a support trellis of the present invention and may be formed in a wide variety of configurations. One example of a stent useful in the present invention is a slotted tubular stent which is designed to radially expand either by balloon catheter or by forming the stent from a temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range. Other stent types, such as tubular-shaped wire stents and self-expandable spring-biased stents are also contemplated. Trellis 24 may therefore be formed from a variety of materials including stainless steel, titanium, platinum, gold and other bio-compatible metals. Shape memory plastics, polymers, and thermoplastic materials which are inert in the body may also be employed to form trellis 24. Shaped memory alloys having superelastic properties generally made from specific ratios of nickel and titanium, commonly known as nitinol, are among the preferred trellis materials,


With additional reference to FIG. 9, scaffold 30 is a substantially cylindrical member having an interior face 34, an exterior face 36 and defines at least one radially-extending scaffold opening 38 communicating therebetween. Interior face 34 of scaffold 30 generally defines passageway 20. It is contemplated by the present invention that scaffold opening 38 need not be completely perimetrically bounded by scaffold 30. Scaffold 30 is formed to have a generally open configuration including a plurality of openings 38 communicating between interior face 34 and exterior face 36. These openings 38 provide for longitudinal flexibility of valve 10 as well as to permit valve 10 to be radially collapsed for delivery through, and radially expanded for deployment in, a body lumen such as a blood vessel. Furthermore, scaffold 30 preferably maintains a substantially coaxial alignment with the body lumen as leaf valve portion 14 deflects between the open and closed configurations so as to better seal passageway 20 when valve 10 is closed.


Leaf valve framework 32 includes a leaf frame 52 corresponding to each valve leaf 40 of leaf valve portion 14. Each leaf frame 52 includes a first and second elongate component legs 54 and 56, respectively. Each leaf frame 52 also has a length which is greater than the radius of the radially-expanded scaffold when implanted so as to minimize the risk of a valve leaf 40 over-deflecting about hinge line 22 towards upstream end 16 of valve 10. Each component leg 54 and 56 includes a proximal end 54a and 56a, and an opposed distal end 54b and 56b, respectively. Each leaf frame 52 is joined to scaffold 30 at a flexible hinge 60 defined by the junction of the proximal ends 54a and 56a of each leg component with scaffold 30. For each valve leaf 40, hinge 60 includes space-apart hinge components 60a, and 60b. Additionally, the distal ends 54b and 56b are contiguously formed. Each hinge component 60a, 60b may be respectively joined to the adjacent hinge component 60b, 60a of the adjacent leaf frame 52 in order to provide improved sealing of valve 10 in the closed configuration. The joining of the hinge components 60a and 60b of adjacent valve leafs 40 further defines annular hinge line 22.


Each leaf frame 52 defines a leaf frame aperture 62 with the distal extent 31 of scaffold 30. Leaf frame aperture 62 communicates between the first and second major surfaces 42 and 44 of valve leaf 40. The shape of leaf frame 52 is selected so as to assist and not inhibit the radial contraction of valve 10 for delivery via catheter through a body lumen. Additionally, leaf frame 52 is formed having a curve imparted thereto so as to provide a concave shape to second major surface 44 of leaf 40. Each leaf frame 52 is imparted with a shape memory so as to extend over passageway 20 in either the open or closed configuration.


Trellis 24 is preferably formed by a single wire 70 contoured to form both scaffold 30 and leaf valve frame 32. As shown in FIG. 6, wire 70 may trace a pattern on a flat surface so as to form a trellis preform 74. Wire 70 may be longitudinally extended and retracted in an undulating pattern such that a valve leaf frame aperture 62 is formed and then a scaffold opening 38 is formed, although other paths are possible. Each leaf frame aperture 62 and each scaffold opening 38 are perimetrically defined by a segment of wire 72 which allows trellis 24 to be radially-collapsible to allow delivery of valve 10 through a body lumen and then radially-expanded at a selected lumen site. Moreover, wire 70 may be welded, fused, crimped, sutured, or otherwise, joined together at strategic locations such as at a scaffold joint 76 defined between circumferentially-adjacent scaffold openings 38. Additionally, wire 70 may be joined at or about hinge joints 76 where adjacent hinge portions 60a and 60b of adjacent valve leaf frames abut.


Referring to FIGS. 7 and 8, trellis preform 74 is bent into the shape of trellis 24 by wrapping preform 74 about an elongate cylindrical mandrel 78 and joining trellis perform ends 74a and 74b together, and then deflecting the leaf frames 52 about hinge line 22 into overlying registry with passageway 20. Trellis 24 may be heat set in this configuration by a method as is typically known for the material which forms trellis 24.


The present invention seals each leaf frame aperture 62 to prevent fluid flow therethrough. The material used to seal each leaf frame aperture 62 is sufficiently thin and pliable so as to permit radially-collapsing the leaf valve portion for delivery by catheter to a location within a body lumen. Referring to FIGS. 10-12, a fluid-impermeable biocompatible non-thrombogenic valve leaf cover 80 may be positioned on trellis 24 so as to seal the leaf frame apertures 62. Preferably, valve leaf cover 80 seals the entire expanse of each leaf frame aperture 62 prior to implantation although it is recognized that the lumen wall will also assist in sealing leaf frame aperture 62 in the region about scaffold 30 adjacent hinge line 22. Therefore, valve leaf cover 80 should minimally seal leaf frame aperture 62 between component legs 54 and 56 and hinge line 22 so that as scaffold 30 becomes embedded in the lumen wall, valve 10 will fully seal at hinge line 22. Valve leaf cover 80 may be formed from a thin layer of, by way of illustration and not by limitation, PE, Pellethane, Urethane, bovine pericardial tissue, and the like. Alternatively, Valve leaf cover may be formed from a surgically-useful textile including, by way of illustration and not by limitation, Dacron, Polyethylene terephthalate (PET), Polyethlylene (PE), silk, Rayon, or the like. Valve leaf cover 80 may also be formed of a surgically-useful polymeric material including, by way of illustration and not by limitation, polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE). Valve leaf cover 80 is desirably coated with a cellular growth-inhibiting drug such as Heparin or Taxol or the like.


Similarly, each valve leaf aperture 62 may be covered with cultured tissue cells derived from a either a donor or the host patient. The cultured tissue cells may be attached to each leaf frame 52 to the distal extent 31 of scaffold 30 so as to seal each valve leaf aperture 62. The cultured tissue cells may be initially positioned on a micro filter type mesh so as to extend either partially or fully into each valve leaf aperture 62. Scaffold 30 and leaf frames 52 may be formed of either a bioabsorbable material or a non-bioabsorbable material so that each will eventually be displaced by the tissue cells as the tissue cells mature. Eventually, then, the cells alone will provide the fully functioning valve, Alternatively, when scaffold 30 and leaf frames 52 are formed from a non-bioabsorbable material, the cultured cells provide a means for reducing any undesirable biological response by the host.



FIGS. 13A-D depict a still further embodiment of the present invention in which adjacent valve leaf frames 24 are joined at a location along the length thereof so as to provide a smaller opening 50′ in the open configuration. Adjacent component legs 54 and 56 may be joined by welding or other techniques so as to form a hinge line 22′ at a location downstream from the distal extent 31 of scaffold 30. As the size of opening 50 affects the required actuation pressure differential acting upon the valve leafs 40, it is contemplated that the precise location at which adjacent valve leaf frames 24 are joined may be selected in accordance with the fluid flow pressure parameters at the site within the body in which the valve of the present invention is emplaced.


Referring again to FIGS. 1-4 and with additional reference to FIGS. 14-16, an elongate generally cylindrical first biocompatible non-thrombogenic liner 82 is attached to trellis 24. First liner 82 may be positioned over either of interior face 34 or exterior face 36 of scaffold 30. First liner 82 may also be provided in addition to, or in place of, valve leaf cover 80 for sealing the leaf frame apertures 62. FIG. 15 depicts first liner 82 positioned on the interior 34 of scaffold 30. Furthermore, first liner 82 may be trimmed to conform closely to the valve leaf frames, as shown in FIG. 15. As shown by FIG. 16, first liner 82 may include a valve webbing 84 trimmed to span between the edges of adjacent valve leafs in the open configuration so as to provide a larger surface area for the body fluid to act upon when urging the valve leafs 40 between the open and closed configuration. First liner 82 may also be trimmed to provide at least one flap 86 extending in the downstream direction beyond each valve leaf 40. Each flap 86 may then be folded through the adjacent valve leaf aperture 62 and laminated to the first liner spanning the other major surface.


Similarly, an elongate generally cylindrical second biocompatible non-thrombogenic liner 88 may be positioned on scaffold 30 opposite first liner 82. Second liner 88 may extend only along a portion of scaffold 30, as shown in FIG. 15, or fully along trellis 24, as shown in FIG. 16. The first and second liners may be joined so as to fully encase either just scaffold 30 or all of trellis 24. Numerous techniques may be employed to laminate or bond first liner 82 to second liner 88 through the scaffold openings 38 and the leaf frame apertures 62 of trellis 34 including heat setting, adhesive welding, application of uniform force and other bonding techniques. Additionally, second liner 88 may be formed by folding an extended length of first liner 82 over upstream end 26 of scaffold 30 so as to extend at least partially along the opposite face of scaffold 30 as first liner 82.


Each of liners 82 and 88 may be capable of inhibitting thrombus formation. Additionally, liners 82 and 88 may either prevent or facilitate tissue ingrowth therethrough, as the particular application for the valve may dictate. For example, liner 88 may be formed from a porous material to facilitate tissue ingrowth therethrough while liner 80 is formed from a material or a treated material which inhibits tissue ingrowth. Liners 80 and 88 may be formed from a surgically-useful textile including, by way of illustration and not by limitation, Dacron, Polyethylene terephthalate (PET), Polyethlylene (PE), silk, Rayon, or the like, Valve leaf cover 80 may also be formed of a surgically-useful polymeric material including, by way of illustration and not by limitation, polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE). It is further contemplated that either liner 82 and 88 may be formed from an xenograft of cellular tissue from a donor such as bovine cardial tissue, or homograft of cellular tissue formed from the host patient.


The polymeric liners 82 and 88 and valve cover 80 of the present invention may be formed by a variety of methods. For example, extrusion processes such as ram extrusion; polymeric casting techniques such as solvent casting and film casting; molding techniques such as blow molding, injection molding and rotational molding; and other thermoforming techniques useful with polymeric materials may be employed and chosen to best serve the type of material used and specific characteristics of the liner or cover desired.


While either or both of the polymeric liners 80 and 88 may be provided directly in tubular form, i.e as an extruded tube, either one or both can also be formed from extruded sheets of material which can be wrapped around all or a portion of the support scaffold to form a cover or liner. Combinations of sheets and tubes are also contemplated and may be applied to the support scaffold in a manner essentially as taught by U.S. patent application Ser. No. 09/035,501, which is herein incorporated by reference. For example, in one embodiment a sheet may be first formed and wrapped externally about the support scaffold and seamed along the longitudinal axis to form a cover. Such a sheet may be made with a high degree of uniaxial orientation. The relative axis of orientation of the stent may vary depending on the material used to form the liner or cover and the orientation and size of its pore structure. For example, in applicants' aforementioned copending U.S. application Ser. No. 08/721,834, the extruded material used to form the liner or cover may be formed from unsintered ePTFE sheets which have been expanded longitudinally and aligned generally longitudinally along the longitudinal stent axis, transverse to the longitudinal direction, or in an off-axis angle therebetween. In another example, a sheet or tube of ePTFE may be stretched and sintered several times to create a preformed ePTFE having expansion memory, such as shown in PCT Publication No. WO 96/00103 (Application No. U.S./95/07326), which is herein incorporated by reference. This publication is based on U.S. priority application Ser. No. 08/265,794, filed Jun. 27, 1994, which is also herein incorporated by reference. The preformed ePTFE allows for further expansion once the stent is implanted and radially deployed. Other embodiments of the present invention include the use of one or more tubes, providing a tube and a sheet formed into a tubular structure, or providing a plurality of sheets formed into a tubular structure on either surface of the stent.


Various bioeffecting agents may also be included in the liners by well known methods. For example, anti-infective agents and/or antithrombogenic agents may be coated on the liner or disposed within some of the pores of the polymeric cover or conformal layer prior to implantation. Additionally, such bioeffecting agents may also be employed on the stent or in the anchoring material used thereon. One example is shown in commonly assigned International Patent Application No. WO 95/29647, published on Nov. 9, 1995 and its 27 U.S. priority applications Ser. No. 235,300, filed Apr. 29, 1994, and Ser. No. 350,233, filed Dec. 1, 1994, which are incorporated herein by reference.


Referring again to FIG. 8, a method of forming a composite endoluminal device of the present invention includes the steps of providing an inner liner 82 on an elongate cylindrical mandrel 78. Trellis 24 is positioned over liner 82. Trellis 24 may be positioned over liner 82 such that an extent 80a of liner 82 may be folded over the upstream end 26 of trellis 24 and positioned over an extent of the exterior face of scaffold 30, as shown in FIG. 15. Extent 80a may be affixed to liner 82 through the scaffold openings 38 or affixed to scaffold 30 itself. Extend 80a may be positioned over the entire length of trellis 24, as shown in FIGS. 1 and 3. Alternatively, a second liner 88 may be positioned on trellis 24 opposite first liner 82.


Still referring to FIG. 8, mandrel 78 may be formed to include a shaped end 78a to serve as a die for shaping the closed configuration of the valve. Shaped end 78a includes a contoured impression 78c for each valve leaf 40. Each valve leaf 40 may be deflected against its contoured impression 78c to provide abutting engagement between the adjacent valve leafs. Trellis 24 may be shaped by shaped end 78a either prior to or after covering with liners 80 or 88. It may be desirable to impart the shape memory to trellis 24 prior attaching the liners. Additionally, while the leaf valve framework 32 is conformed to shaped end 78a, the valve leafs 40 may be joined in accordance with the embodiment of FIGS. 13A-D, either before or after attaching one or both of liners 80 and 88. It is further contemplated that each impression 78c may itself provide a contoured surface for imparting a curve to the deflected valve leafs 40.


The present invention further contemplates positioning trellis 24 about mandrel 78 without an underlying lining. Trellis 24 may then receive first lining over only the exterior face 36 of scaffold 30. Lining 80 may further be extended so as to cover the leaf frame apertures 62 of leaf valve frame 52, although it is contemplated using a different material to cover the leaf frame apertures 62. Lining 80 may also provide a valve webbing spanning between adjacent valve leafs 40.


It is additionally contemplated by the present invention to leave scaffold 30 substantially uncovered and to seal each leaf frame aperture 62 to the extent required to provide an acceptable degree of flow restriction in the closed configuration. While leaf frame apertures 62 are desirably fully sealed prior to implantation, it is contemplated that only that portion of leaf frame aperture 62 which extends in registry with fluid passageway 20 be sealed by one or more liners 80. The embedding of scaffold 30 into the body lumen would thereby provide valve 10 with an acceptable degree of fluid-integrity about the lumen wall. In such an embodiment, valve leaf cover 80 may be applied to trellis 24 to fully seal leaf frame aperture 62. The preferred method includes attaching a cover to both frame component legs 54 and 56 and to the segment of distal scaffold extent 31 between the corresponding hinges.


Liners 82 and 88 may be formed of a polymeric material which may be fused by various techniques such as heat sealing, solvent bonding, adhesive bonding, or use of coatings. It is also contemplated that liners 80 and 88 may be formed of a textile material, or that each could include a homograft or xenograft tissue retained by the intermediate member to seal the openings in same. The formation, application, and orientation of liners 80 and 88 may be accomplished by the techniques described in commonly-assigned and copending U.S. patent application Ser. No. 09/035,501, entitled “Conformal Laminate Stent Device”, which is incorporated by reference herein.



FIG. 17 shows an alternate embodiment of a trellis 148 for valve 110 in which trellis 30 of valve 10 is mechanically joined to a second radially collapsible scaffold 150. It is also contemplated that trellis 30 of valve 10 may be continuously formed by the same wire 170 which forms second scaffold 150. The present invention contemplates that elongate portions 170a of wire 170 may be employed between sections of scaffolds to allow the prosthetic valve 10 to be emplaced within tortuously-extending sections of body lumen.



FIGS. 18-21 depict yet another embodiment of the present invention in which the valve leafs of an implantable prosthetic valve 110 are attached to the interior luminal surface 114 of a second radially collapsible tubular fluid conduit 112. Second conduit 112 may be selected from many known stent and covered stent designs known in the art. Second conduit 112 further maintains the patency of the body lumen to either side of valve 10 and may also include a biocompatible fluid impermeable non-thrombogenic lining 116 on either or both of its own interior or exterior lumenal surfaces, 114 and 115, respectively. The materials used to form the second tubular fluid conduit may also be selected to be either bioabsorbable or non-bioabsorbable as previously described for liners 80 and 88.


Second conduit 112 includes a radially collapsible skeleton 120 which may be formed from a shape memory alloy, an elastic metal, or a polymer. Second conduit 112 may also be formed of a bioabsorbable material. Outer surface 115 of second conduit 112 need not be covered as skeleton 120 will eventually embed into the lumen wall, but a lining 116 may be preferable so as to limit flow-around until that time.


As shown in FIG. 19, a non-absorbable tether line 125 may have ends 125a and 125b affixed between second conduit 112 and each valve leaf 40 to prevent the leafs from inverting towards the upstream end 126 of secondary conduit should the back flow pressure become sufficient to over-deflect the leafs past hinge line 22. Tether line 125 is desirably affixed at ends 125a and 125 to non-bioabsorbable components of valve 110.


With additional reference to FIG. 21, it is also contemplated by the present invention to mechanically attach a number of covered leaf frames 130 to the interior luminal surface 114 of second conduit 112. Covered leaf frames 130 are similar in construction to valve leafs 40 of valve 10. Each covered leaf frame 130 includes a first and second elongate component leg 132 and 134 welded or otherwise affixed to skeleton 120 at a hinge portion 135 comprising hinges 135a and 135b where the component legs attach. Covered leaf frame 130 defines a leaf frame aperture 136 with skeleton 120 between the associated hinges 135a and 135b. A leaf cover 140 is desirably affixed over each leaf frame aperture 136 by spanning from each component leg 132 and 134 to skeleton 120 between the hinges 135a and 135b so as to provide a fluid integrity to the valve in the closed configuration. Alternatively, the covered leaf frames could be attached to surface 114 along a leaf frame stem 130a.


Referring now to FIGS. 22 and 23, a prosthetic bicuspid valve 900 of the prior art is depicted. Valve 900 is typical of a bubble valve design which provides first and second valve leafs, 902 and 904. Valve 900 is formed having a solid interior stent frame which provides a pair of opposed raised posts which form raised hubs 906a and 906b. The interior stent is covered with a generally cylindrical cover 908 which itself is formed of a flexible material. Valve flaps 902 and 904 are formed by the portion of cover 908 extending unsupported beyond the interior stent structure. Valve flaps 902 and 904 must therefore rely on the resiliency and shape memory of the material of the cover 908 for any bias towards the open or closed configurations, As shown in FIG. 23, cover 908 terminates at a flap edge 910 which, in the open configuration, defines a substantially circular opening through valve 900. In the closed configuration, shown in FIG. 22, flap edge 910 extends along a substantially catenary path between raised hubs 906a and 906b to seal valve 900.



FIGS. 24A-26 depict a prosthetic bicuspid valve 210 of the present invention. With like numbers indicating like components to other embodiments of the present invention, bicuspid valve 210 is a bubble valve including a support trellis 224 and a fluid impermeable non-thrombogenic lining 280. Valve 210 is contemplated as a replacement aortic valve. Valve 210 is constructed from biocompatible materials so as to minimize any adverse body reaction to its implantation.


Valve 210 includes an elongate tubular body portion 212 and a leaf valve portion 214. Valve 210 includes an upstream end 216, a downstream end 218, and an elongate fluid passageway 220 extending therebetween along a valve axis 1v. Leaf valve portion 214 extends in overlying registry with passageway 220 and includes first and second valve leafs 240 and 241 which are deflectable between a closed configuration, shown in FIGS. 24A and 24B, restricting fluid flow through passageway 220, and an open configuration, shown in FIGS. 25A and 25B, permitting fluid flow through passageway 220. Valve 210 also includes a pair of diametrically-opposed valve hinge hubs 242 and 244 about which valve leafs 240 and 241 deflect between the open and closed configurations. Hinge hubs 242 and 244 are located downstream of valve leafs 240 and 241 when valve 210 is in the closed configuration.


Valve leafs 240 and 241 are similarly-sized and -shaped and include opposed first and second major surfaces 240a, 241a and 240b, 241b, respectively. Each first major surface 240a, 241a of a valve leaf 240 is oriented in facing opposition towards upstream end 216 of valve 210. Valve leafs 240 and 241 further include an arcuate leaf edge 240c and 241c, respectively, which are positionable in abutting engagement along a substantially catenary curve between hinge hubs 242 and 244 to define the closed configuration of valve 210. Similarly, as best shown in FIG. 4, the leaf edges 240c and 241c define an eye-shaped valve leaf opening 250 when in the open configuration. Valve leaf opening 250 is in fluid communication with passageway 220. Whereas the valve leafs of the sawtooth valves of the present invention desirably had a longitudinal length greater than the radius of the implanted scaffold, valve leafs of the bicuspid valves of the present invention may be formed having a longitudinal length dimension 1 which is smaller than the radius of the implanted scaffold portion.


Valve leafs 240 and 241 are desirably formed having a spring bias about hinge hubs 242 and 244 towards the closed configuration. The open configuration may be attained when the fluid pressure acting on the first major surfaces 240a and 241a of the valve leafs 240 and 241 overcomes both the fluid pressure acting on the second major surfaces 240b and 241b of the valve leafs 240 of valve 210 and the spring bias imparted to the valve leafs 240 acting to close the valve leafs. Similarly, when the fluid pressure from the downstream end 218 of valve 210 become too great relative to the upstream fluid pressure, the valve leafs 240 will be urged towards the closed configuration to thwart fluid flow through the valve back towards the upstream end 228.



FIGS. 26A-C show the support trellis 224 employed by valve 210. Trellis 224 may be formed from a material exhibiting shape memory characteristics or from a material which is readily expandable by a balloon catheter. Trellis 224 is generally an elongate tube being coaxial with valve axis 1v. Trellis 224 has opposed upstream and downstream ends 226 and 228. Upstream end 226 of trellis 224 is further defined by a radially collapsible body scaffold 230. Downstream end 228 of trellis 224 is further defined by a radially-collapsible leaf valve framework 232.


Trellis 224 may be formed from a wide variety of materials and in a variety of configurations. Radially-expandable endovascular stents known in the art provide useful basic designs for modification into a support trellis of the present invention and may be formed in a wide variety of configurations. One example of a stent useful in the present invention is a slotted tubular stent which is designed to radially expand either by balloon catheter or by forming the stent from a temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range. Other stent types, such as tubular-shaped wire stents and self-expandable spring-biased stents are also contemplated. Trellis 224 may therefore be formed from a variety of materials including stainless steel, titanium, platinum, gold and other bio-compatible metals. Shape memory plastics and thermoplastic materials which are inert in the body may also be employed to form trellis 224. Shaped memory alloys having superelastic properties generally made from specific ratios of nickel and titanium, commonly known as nitinol, are among the preferred trellis materials.


Scaffold 230 is a substantially cylindrical member having an interior face 234, an exterior face 236 and defines at least one radially-extending scaffold opening 238 communicating therebetween. Interior face 234 of scaffold 230 generally defines passageway 220. It is contemplated by the present invention that scaffold opening 238 need not be perimetrically bounded by scaffold 230. Scaffold 230 is formed to have a generally open configuration including a plurality of openings 238 communicating between interior face 234 and exterior face 236. These openings 238 provide for longitudinal flexibility of valve 210 as well as to permit valve 210 to be radially collapsed for delivery through, and radially expanded for deployment in, a body lumen such as a blood vessel. Furthermore, scaffold 230 preferably maintains a substantially coaxial alignment with the body lumen as leaf valve portion 214 deflects between the open and closed configurations so as to better seal passageway 220 when valve 210 is closed.


Leaf valve framework 232 includes leaf frames 252 and 253 corresponding to valve leafs 240 and 241. Leaf frames 252 and 253 define leaf frame apertures 262 and 263 with the distal extent 231 of scaffold 230. Leaf frame apertures 262 and 263 communicate between first and second major surfaces 240a and 240b of valve leaf 240, and first and second major surfaces 241a and 241b of valve leaf 241, respectively. Leaf frames 252 and 253 may be radially contracted towards valve axis 1v, for delivery via catheter through a body lumen. Leaf frames 252 and 253 are imparted with a shape memory so as to extend over passageway 220 once implanted in a body lumen.


Leaf valve framework 232 further includes diametrically opposed hinge posts 245 and 247 extending from distal end 231 of scaffold 230 towards hinge hubs 242 and 244, respectively. Hinge hubs 242 and 244 extend transversely to valve axis 1v. Arcuate frame portions 257 and 259 of valve leafs 240 and 241 extend between hinge hubs 242 and 244 along a substantially catenary path. As shown in FIGS. 25B and 26C, arcuate frame portions 257 and 259 deflect about hinge hubs 242 and 244 and swings towards and away from each other as valve leafs 240 and 241 are urged between the closed and open configurations.


Each leaf frame aperture 262 and each scaffold opening 238 are perimetrically defined by a segment of wire 270 which allows trellis 224 to be radially-collapsible so as to allow delivery of valve 210 through a body lumen and then radially-expanded at a selected lumen site. Moreover, wire 270 may be welded, fused, crimped, sutured, or otherwise, joined together at strategic locations, such as at a scaffold joint 276 defined between circumferentially-adjacent scaffold openings 238.


Trellis 224 is preferably formed by a single wire 270 contoured to form both scaffold 230 and leaf valve frame 232. Wire 270 may be longitudinally extended and retracted in an undulating pattern such that one half of scaffold 230 is formed and a then a portion or all of valve leaf frame 232 prior to completing scaffold 230, although other paths are possible. Alternatively still, trellis 224 may be formed in constituent components which are then joined. Other methods for forming trellis 224 as a unitary member will thus be apparent to those skilled in the art.


Liner 280 may be formed in accordance with the description for liner 80 hereinabove. Liner 280 may be applied to trellis 224 at either interior face 234, exterior face 236, or at both faces. Liner 280 may further be affixed only to trellis 224 or may include portions which are adhered to itself through the scaffold openings 238 and/or the leaf frame apertures 262 and 263. It is contemplated that one of inner liner 280a and outer liner 280b may be forced though trellis 224 to be affixed to the other or both may be joined together within the scaffold openings 238 or the leaf frame apertures 262, 263.


The present invention further contemplates that the liner 280 forming the major surfaces of valve leafs 240 and 241 are urgable into a concave shape so as to better collect backflow and urge the valve leafs towards the open or closed configuration. The major surfaces of valve leafs 240 and 241 have complex shapes which are a function of the longitudinal spacing of catenary frame portion from distal end 231 of scaffold 230. Furthermore, the material forming the major surfaces need not taughtly-extend across the leaf frame openings of valve leafs 240 and 241. The present invention contemplates providing sufficient excess material spanning leaf frame apertures 262 and 263 such that overwhelming fluid pressure acting on one major surface of a valve leaf forces the covering through the valve leaf opening. When excess material is applied across valve leaf apertures 262 and 263, then the first major surfaces of each valve leaf 240 and 241 may assume a concave shape so as to favor the opening the valve leafs and the second major surfaces may assume a concave shape so as to favor closing the valve leafs.



FIGS. 27A-29B depict an alternate embodiment of a bicuspid valve of the present invention. Valve 310 is similar in most respects to valve 210 described hereinabove but includes valve leafs 340 and 341 defined by leaf frame edges 357 and 359 having larger radius of curvature between hinge hubs 342 and 344 than is shown in FIGS. 2-5. The larger radius of curvature along leaf frame edges 357 and 359 results in larger major surfaces for the opposed valve leafs 340 and 341 and defines a smaller opening 350 in the open configuration, as shown in FIG. 28B. It is contemplated that leaf frame edges 357 and 359 are deflectable to a position coextensive with hinge hubs 342 and 344, as shown in FIG. 29B, or to a position downstream of hinge hubs 342 and 344, as shown in FIG. 28B. It is also contemplated that the first major surfaces 340a and 341a may come into contact when valve leafs 340 and 341 are in the closed configuration.


While the present invention has been shown and described in detail above, it will be clear to the person skilled in the art that changes and modifications may be made without departing from the spirit and scope of the invention. That which is set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation. The actual scope of the invention is intended to be defined by the following claims.

Claims
  • 1. A valve, comprising: a radially-elastic scaffold with valve leaflet frames having an open-frame construction; andan elongate liner adjacent the radially-elastic scaffold and valve leaflet frames to provide a fluid passageway, where the elongate liner includes excess material to provide a concave shape to the elongate liner extending into the open-frame construction, and where the valve leaflet frames with the elongate liner move between a closed position to restrict fluid flow through the fluid passageway and an open position to allow fluid flow through the passageway.
  • 2. The valve of claim 1, further including a microfilter support mesh over the open-frame construction of the valve leaflet frames to support cultured tissue cells seeded on to the elongate liner.
  • 3. The valve of claim 1, wherein the valve leaflet frames of the radially-elastic scaffold are mechanically biased towards the open position.
  • 4. The valve of claim 1, wherein the valve leaflet frames of the radially-elastic scaffold are mechanically biased towards the closed position.
  • 5. The valve of claim 1, wherein the elongate liner is positioned over the radially-elastic scaffold and a second liner is positioned on the radially-elastic scaffold opposite the elongate liner.
  • 6. The valve of claim 1, wherein the radially-elastic scaffold attaches to an interior surface of a second radially collapsible prosthetic fluid conduit.
  • 7. The valve of claim 6, wherein the second radially collapsible prosthetic fluid conduit is a stent.
  • 8. A valve, comprising: a radially deformable unitary open-frame scaffold having a tubular body and valve leaflet frames; anda liner at least partially encasing the radially deformable unitary open-frame scaffold to provide a fluid passageway, where the liner includes excess material to provide a concave shape to the liner extending into the open-frame scaffold, and where the valve leaflet frames with the liner move between a closed position to restrict fluid flow through the fluid passageway and an open position to allow fluid flow through the passageway.
  • 9. The valve of claim 8, further including a flexible hinge supporting each of the valve leaflet frames on the tubular body.
  • 10. The valve of claim 8, wherein the radially deformable unitary open-frame scaffold expands from a first diameter to a second radially-expanded diameter.
  • 11. The valve of claim 10, wherein the radially deformable unitary open-frame scaffold expands through the use of a delivery balloon.
  • 12. The valve of claim 10, wherein the radially deformable unitary open-frame scaffold is formed from a shape memory material that self-expands from the first diameter to the second radially-expanded diameter.
  • 13. The valve of claim 8, wherein the elongate liner is positioned over the radially deformable unitary open-frame scaffold and a second liner is positioned on the radially deformable unitary open-flame scaffold opposite the elongate liner.
  • 14. A medical system, comprising: a valve having:a radially-elastic scaffold with valve leaflet frames having an open-frame construction; andan elongate liner adjacent the radially-elastic scaffold and valve leaflet frames to provide a fluid passageway, where the elongate liner includes excess material to provide a concave shape to the elongate liner extending into the open-frame construction, and where the valve leaflet frames with the elongate liner move between a closed position to restrict fluid flow through the fluid passageway and an open position to allow fluid flow through the passageway; anda second radially collapsible prosthetic fluid conduit, wherein the radially-elastic scaffold attaches to an interior surface of the second radially collapsible prosthetic fluid conduit.
  • 15. The medical system of claim 14, wherein the second radially collapsible prosthetic fluid conduit is a stent.
  • 16. The medical system of claim 14, wherein the valve leaflet frames of the radially-elastic scaffold are mechanically biased towards the open position.
  • 17. The medical system of claim 14, wherein the valve leaflet frames of the radially-elastic scaffold are mechanically biased towards the closed position.
  • 18. The medical system of claim 14, wherein the elongate liner is positioned over the radially-elastic scaffold and a second liner is positioned on the radially-elastic scaffold opposite the elongate liner.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 10/714,034, filed Nov. 14, 2003, now U.S. Pat No. 6,840,957, which is a continuation of U.S. application Ser. No. 10/191,667, filed Jul. 9, 2002, and now U.S. Pat. No. 6,685,739, which is a division of U.S. application Ser. No. 09/425,142, filed Oct. 21, 1999, now U.S. Pat. No. 6,440,164 B1.

US Referenced Citations (648)
Number Name Date Kind
15192 Pearle Jun 1856 A
3671979 Moulopoulos Jun 1972 A
4291420 Reul Sep 1981 A
4759759 Walker et al. Jul 1988 A
4787901 Baykut Nov 1988 A
4851001 Taheri Jul 1989 A
4872874 Taheri Oct 1989 A
4935030 Alonso Jun 1990 A
4994077 Dobben Feb 1991 A
5002567 Bona et al. Mar 1991 A
5123919 Sauter et al. Jun 1992 A
5141491 Bowald Aug 1992 A
5163953 Vince Nov 1992 A
5219355 Parodi et al. Jun 1993 A
5254127 Wholey et al. Oct 1993 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5358518 Camilli Oct 1994 A
5370685 Stevens Dec 1994 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5413599 Imachi et al. May 1995 A
5469868 Reger Nov 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5643208 Parodi Jul 1997 A
5693087 Parodi Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5735859 Fischell et al. Apr 1998 A
5741326 Solovay Apr 1998 A
5741333 Frid Apr 1998 A
5759830 Vacanti et al. Jun 1998 A
5770193 Vacanti et al. Jun 1998 A
5770417 Vacanti et al. Jun 1998 A
5800506 Perouse Sep 1998 A
5824061 Quijano et al. Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843180 Jaffe et al. Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5863531 Naughton et al. Jan 1999 A
5879320 Cazenave Mar 1999 A
5895419 Tweden et al. Apr 1999 A
5910170 Reimink et al. Jun 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
6010531 Donlon et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6027525 Suh et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6110201 Quijano et al. Aug 2000 A
6126686 Badylak et al. Oct 2000 A
6139575 Shu et al. Oct 2000 A
6254564 Wilk et al. Jul 2001 B1
6287334 Moll et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6312447 Grimes Nov 2001 B1
6355030 Aldrich et al. Mar 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6451054 Stevens Sep 2002 B1
6454799 Schreck Sep 2002 B1
6461366 Seguin Oct 2002 B1
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6564805 Garrison et al. May 2003 B2
6569196 Vesely May 2003 B1
6602286 Strecker Aug 2003 B1
6629534 St. Goar et al. Oct 2003 B1
6635085 Caffey et al. Oct 2003 B1
6666885 Moe Dec 2003 B2
6666886 Tranquillo et al. Dec 2003 B1
6669725 Scott Dec 2003 B2
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6676702 Mathis Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6692512 Jang Feb 2004 B2
6695866 Kuehn et al. Feb 2004 B1
6695878 McGuckin, Jr. et al. Feb 2004 B2
6709456 Langberg et al. Mar 2004 B2
6709457 Otte et al. Mar 2004 B1
6716241 Wilder et al. Apr 2004 B2
6716244 Klaco Apr 2004 B2
6719767 Kimblad Apr 2004 B1
6719784 Henderson Apr 2004 B2
6719786 Ryan et al. Apr 2004 B2
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6719790 Brendzel et al. Apr 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6723122 Yang et al. Apr 2004 B2
6723123 Kazatchkov et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6726716 Marquez Apr 2004 B2
6726717 Alfieri et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6730122 Pan et al. May 2004 B1
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6749630 McCarthy et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6752828 Thornton Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6761734 Suhr Jul 2004 B2
6761735 Eberhardt et al. Jul 2004 B2
6764494 Menz et al. Jul 2004 B2
6764508 Roehe et al. Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6767362 Schreck Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6770083 Seguin Aug 2004 B2
6780200 Jansen Aug 2004 B2
6786924 Ryan et al. Sep 2004 B2
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790231 Liddicoat et al. Sep 2004 B2
6793673 Kowalsky et al. Sep 2004 B2
6797000 Simpson et al. Sep 2004 B2
6797001 Mathis et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6802860 Cosgrove et al. Oct 2004 B2
6805710 Bolling et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6810882 Langberg et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824562 Mathis et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6837902 Nguyen et al. Jan 2005 B2
6840246 Downing Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6846324 Stobie Jan 2005 B2
6846325 Liddicoat Jan 2005 B2
6858039 McCarthy Feb 2005 B2
6869444 Gabbay Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875224 Grimes Apr 2005 B2
6875230 Morita et al. Apr 2005 B1
6875231 Anduiza et al. Apr 2005 B2
6881199 Wilk et al. Apr 2005 B2
6881224 Kruse et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6890352 Lentell May 2005 B1
6890353 Cohn et al. May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896700 Lu et al. May 2005 B2
6902576 Drasler et al. Jun 2005 B2
6908478 Alferness et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6913608 Liddicoat et al. Jul 2005 B2
6916338 Speziali Jul 2005 B2
6918917 Nguyen et al. Jul 2005 B1
6921407 Nguyen et al. Jul 2005 B2
6921811 Zamora et al. Jul 2005 B2
6926715 Hauck et al. Aug 2005 B1
6926730 Nguyen et al. Aug 2005 B1
6929653 Strecter Aug 2005 B2
6932838 Schwartz et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939359 Tu et al. Sep 2005 B2
6942694 Liddicoat et al. Sep 2005 B2
6945957 Freyman Sep 2005 B2
6945978 Hyde Sep 2005 B1
6945996 Sedransk Sep 2005 B2
6945997 Huynh et al. Sep 2005 B2
6949122 Adams et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6951573 Dilling Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6955689 Ryan et al. Oct 2005 B2
6958076 Acosta et al. Oct 2005 B2
6962605 Cosgrove et al. Nov 2005 B2
6964682 Nguyen-Thien-Nhon et al. Nov 2005 B2
6964683 Kowalsky et al. Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6966925 Stobie Nov 2005 B2
6966926 Mathis Nov 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976995 Mathis et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6986775 Morales et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6997950 Chawla Feb 2006 B2
6997951 Solem et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7007396 Rudko et al. Mar 2006 B2
7011669 Kimblad Mar 2006 B2
7011681 Vesely Mar 2006 B2
7011682 Lashinski et al. Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018407 Wright et al. Mar 2006 B1
7018408 Bailey et al. Mar 2006 B2
7022134 Quijano et al. Apr 2006 B1
7025780 Gabbay Apr 2006 B2
7033390 Johnson et al. Apr 2006 B2
7037333 Myers et al. May 2006 B2
7037334 Hlavka et al. May 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7044967 Solem et al. May 2006 B1
7048754 Martin et al. May 2006 B2
7048757 Shaknovich May 2006 B2
7052487 Cohn et al. May 2006 B2
7052507 Wakuda et al. May 2006 B2
7063722 Marquez Jun 2006 B2
7066954 Ryan et al. Jun 2006 B2
7070616 Majercak et al. Jul 2006 B2
7070618 Streeter Jul 2006 B2
7077862 Vidlund et al. Jul 2006 B2
7081131 Thornton Jul 2006 B2
7087064 Hyde Aug 2006 B1
7089051 Jäverud et al. Aug 2006 B2
7090695 Solem et al. Aug 2006 B2
20020013571 Goldfarb et al. Jan 2002 A1
20020026216 Grimes Feb 2002 A1
20020082630 Menz et al. Jun 2002 A1
20020123802 Snyders Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020183835 Taylor et al. Dec 2002 A1
20020183838 Liddicoat et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030050694 Yang et al. Mar 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030163194 Quijano et al. Aug 2003 A1
20030167071 Martin et al. Sep 2003 A1
20030171806 Mathis et al. Sep 2003 A1
20030199975 Gabbay Oct 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20030229395 Cox Dec 2003 A1
20030233142 Morales et al. Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20030236569 Mathis et al. Dec 2003 A1
20040002719 Oz et al. Jan 2004 A1
20040003819 St. Goar et al. Jan 2004 A1
20040010305 Alferness et al. Jan 2004 A1
20040015230 Moll et al. Jan 2004 A1
20040015232 Shu et al. Jan 2004 A1
20040015233 Jansen Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040019377 Taylor et al. Jan 2004 A1
20040019378 Hlavka et al. Jan 2004 A1
20040024447 Haverich Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040024452 Kruse et al. Feb 2004 A1
20040030321 Fangrow, Jr. Feb 2004 A1
20040030381 Shu Feb 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040030405 Carpentier et al. Feb 2004 A1
20040034380 Woolfson et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040039442 St. Goar et al. Feb 2004 A1
20040039443 Solem et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044365 Bachman Mar 2004 A1
20040044403 Bischoff et al. Mar 2004 A1
20040049207 Goldfarb et al. Mar 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059351 Eigler et al. Mar 2004 A1
20040059411 Strecker Mar 2004 A1
20040059412 Lytle, IV et al. Mar 2004 A1
20040060161 Leal et al. Apr 2004 A1
20040073301 Donlon et al. Apr 2004 A1
20040073302 Rourke et al. Apr 2004 A1
20040078072 Tu et al. Apr 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040082923 Field Apr 2004 A1
20040082991 Nguyen et al. Apr 2004 A1
20040087975 Lucatero et al. May 2004 A1
20040088045 Cox May 2004 A1
20040088046 Speziali May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093080 Helmus et al. May 2004 A1
20040097979 Svanidze et al. May 2004 A1
20040098098 MCGuckin, Jr. et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102839 Cohn et al. May 2004 A1
20040102840 Solem et al. May 2004 A1
20040102842 Jansen May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040106991 Hopkins et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122448 Levine Jun 2004 A1
20040122512 Navia et al. Jun 2004 A1
20040122513 Navia et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122515 Chu Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127980 Kowalsky et al. Jul 2004 A1
20040127981 Rahdert et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133267 Lane Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040138745 Macoviak et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148019 Vidlund et al. Jul 2004 A1
20040148020 Vidlund et al. Jul 2004 A1
20040153052 Mathis Aug 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040153147 Mathis Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040167539 Keuhn et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172046 Hlavka et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040176840 Langberg et al. Sep 2004 A1
20040181238 Zarbatany et al. Sep 2004 A1
20040186444 Daly et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186561 McGuckin, Jr. et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193253 Thorpe et al. Sep 2004 A1
20040193260 Alferness et al. Sep 2004 A1
20040199155 Mollenauer Oct 2004 A1
20040199183 Oz et al. Oct 2004 A1
20040199191 Schwartz Oct 2004 A1
20040204758 Eberhardt et al. Oct 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210240 Saint Oct 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210303 Sedransk Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210305 Shu et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220654 Mathis et al. Nov 2004 A1
20040220657 Nieminen et al. Nov 2004 A1
20040225322 Garrison et al. Nov 2004 A1
20040225344 Hoffa et al. Nov 2004 A1
20040225348 Case et al. Nov 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230297 Thornton Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20040236419 Milo Nov 2004 A1
20040243153 Liddicoat et al. Dec 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040243228 Kowalsky et al. Dec 2004 A1
20040243230 Navia et al. Dec 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260276 Rudko et al. Dec 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260322 Rudko et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050004583 Oz et al. Jan 2005 A1
20050004667 Swinford et al. Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050027261 Weaver et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050027351 Reuter et al. Feb 2005 A1
20050027353 Alferness et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033419 Alferness et al. Feb 2005 A1
20050033446 Deem et al. Feb 2005 A1
20050038506 Webler et al. Feb 2005 A1
20050038507 Alferness et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050043792 Solem et al. Feb 2005 A1
20050049679 Taylor et al. Mar 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050049697 Sievers Mar 2005 A1
20050054977 Laird et al. Mar 2005 A1
20050055079 Duran Mar 2005 A1
20050055087 Starksen Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050055089 Macoviak et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050065460 Laird Mar 2005 A1
20050065550 Starksen et al. Mar 2005 A1
20050065594 Dimatteo et al. Mar 2005 A1
20050065597 Lansac Mar 2005 A1
20050070998 Rourke et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075659 Realyvasquez et al. Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075723 Schroeder et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075728 Nguyen et al. Apr 2005 A1
20050075729 Nguyen et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080483 Solem et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050085903 Lau Apr 2005 A1
20050085904 Lemmon Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050096739 Cao May 2005 A1
20050096740 Langberg et al. May 2005 A1
20050101975 Nguyen et al. May 2005 A1
20050102026 Turner et al. May 2005 A1
20050107810 Morales et al. May 2005 A1
20050107811 Starksen et al. May 2005 A1
20050107812 Starksen et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119673 Gordon et al. Jun 2005 A1
20050119734 Spence et al. Jun 2005 A1
20050119735 Spence et al. Jun 2005 A1
20050125011 Spence et al. Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137449 Nieminen et al. Jun 2005 A1
20050137450 Aronson et al. Jun 2005 A1
20050137451 Gordon et al. Jun 2005 A1
20050137676 Richardson et al. Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137685 Nieminen et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137700 Spence et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050143810 Dauner et al. Jun 2005 A1
20050143811 Realyvasquez Jun 2005 A1
20050149014 Hauck et al. Jul 2005 A1
20050149179 Mathis et al. Jul 2005 A1
20050149180 Mathis et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050159810 Filsoufi Jul 2005 A1
20050159811 Lane Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165478 Song Jul 2005 A1
20050171472 Lutter Aug 2005 A1
20050171601 Cosgrove et al. Aug 2005 A1
20050177227 Heim et al. Aug 2005 A1
20050177228 Solem et al. Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050184122 Hlavka et al. Aug 2005 A1
20050187614 Agnew Aug 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050187617 Navia Aug 2005 A1
20050192606 Paul, Jr. et al. Sep 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197692 Pai et al. Sep 2005 A1
20050197693 Pai et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216039 Lederman Sep 2005 A1
20050216077 Mathis et al. Sep 2005 A1
20050216078 Starksen et al. Sep 2005 A1
20050222675 Sauter Oct 2005 A1
20050222678 Lashinski et al. Oct 2005 A1
20050228422 Machold et al. Oct 2005 A1
20050228479 Pavcnik et al. Oct 2005 A1
20050228486 Case et al. Oct 2005 A1
20050228494 Marquez Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050228496 Mensah et al. Oct 2005 A1
20050234541 Hunt et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240202 Shennib et al. Oct 2005 A1
20050240255 Schaeffer Oct 2005 A1
20050240259 Sisken et al. Oct 2005 A1
20050240262 White Oct 2005 A1
20050244460 Alferiev et al. Nov 2005 A1
20050246013 Gabbay Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050261704 Mathis Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267493 Schreck et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050267565 Dave et al. Dec 2005 A1
20050267571 Spence et al. Dec 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20050267574 Cohn et al. Dec 2005 A1
20050272969 Alferness et al. Dec 2005 A1
20050273160 Lashinski et al. Dec 2005 A1
20050278015 Dave et al. Dec 2005 A1
20050283178 Flagle et al. Dec 2005 A1
20050288779 Shaoulian et al. Dec 2005 A1
20060000715 Whitcher et al. Jan 2006 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060009804 Pederson Jan 2006 A1
20060009841 McGuckin, Jr. et al. Jan 2006 A1
20060009842 Huynh et al. Jan 2006 A1
20060013805 Hebbel et al. Jan 2006 A1
20060013855 Carpenter et al. Jan 2006 A1
20060015136 Besselink Jan 2006 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060015179 Bulman-Fleming et al. Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020332 Lashinski et al. Jan 2006 A1
20060020334 Lashinski et al. Jan 2006 A1
20060020335 Kowalsky et al. Jan 2006 A1
20060020336 Liddicoat Jan 2006 A1
20060025750 Startksen et al. Feb 2006 A1
20060025784 Startksen et al. Feb 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060025854 Lashinski et al. Feb 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025856 Ryan et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030747 Kantrowitz et al. Feb 2006 A1
20060030866 Schreck Feb 2006 A1
20060030882 Adams et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060036317 Vidlund et al. Feb 2006 A1
20060041305 Lauterjung Feb 2006 A1
20060041306 Vidlund et al. Feb 2006 A1
20060047297 Case Mar 2006 A1
20060047338 Jenson Mar 2006 A1
20060047343 Oviatt et al. Mar 2006 A1
20060052804 Mialhe Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058817 Starksen et al. Mar 2006 A1
20060058865 Case et al. Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060058889 Case et al. Mar 2006 A1
20060064115 Allen et al. Mar 2006 A1
20060064116 Allen et al. Mar 2006 A1
20060064118 Kimblad Mar 2006 A1
20060064174 Zadno Mar 2006 A1
20060069400 Burnett et al. Mar 2006 A1
20060069429 Spence et al. Mar 2006 A1
20060069430 Rahdert et al. Mar 2006 A9
20060074483 Schrayer Apr 2006 A1
20060074484 Huber Apr 2006 A1
20060074485 Realyvasquez Apr 2006 A1
20060085060 Campbell Apr 2006 A1
20060089708 Osse et al. Apr 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060095125 Chinn et al. May 2006 A1
20060099326 Keogh et al. May 2006 A1
20060100697 Casanova May 2006 A1
20060100699 Vidlund et al. May 2006 A1
20060106278 Machold et al. May 2006 A1
20060106279 Machold et al. May 2006 A1
20060106456 Machold et al. May 2006 A9
20060111660 Wolf et al. May 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060111774 Samkov et al. May 2006 A1
20060116572 Case Jun 2006 A1
20060116756 Solem et al. Jun 2006 A1
20060122686 Gilad et al. Jun 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060122693 Biadillah et al. Jun 2006 A1
20060127443 Helmus Jun 2006 A1
20060129235 Seguin et al. Jun 2006 A1
20060129236 McCarthy Jun 2006 A1
20060135476 Kutryk et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060135967 Realyvasquez Jun 2006 A1
20060136044 Osborne Jun 2006 A1
20060136045 Flagle et al. Jun 2006 A1
20060136052 Vesely Jun 2006 A1
20060136054 Berg et al. Jun 2006 A1
20060142846 Pavcnik et al. Jun 2006 A1
20060142847 Shaknovich Jun 2006 A1
20060142848 Grabbay Jun 2006 A1
20060142854 Alferness et al. Jun 2006 A1
20060149358 Zilla et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060149367 Sieracki Jul 2006 A1
20060149368 Spence Jul 2006 A1
20060161133 Laird et al. Jul 2006 A1
20060161248 Case et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060161250 Shaw Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060167542 Quintessenza Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
Foreign Referenced Citations (171)
Number Date Country
0 380 666 Aug 1990 EP
0 466 518 Jan 1992 EP
0 520 126 Dec 1992 EP
0 850 607 Jul 1998 EP
2 728 457 Jun 1996 FR
2 788 217 Jul 2000 FR
WO8800459 Jan 1988 WO
WO9015582 Dec 1990 WO
WO9404099 Mar 1994 WO
WO9501669 Jan 1995 WO
WO9619159 Jun 1996 WO
WO9803656 Jan 1998 WO
WO9832400 Jul 1998 WO
WO9846115 Oct 1998 WO
WO9904724 Feb 1999 WO
WO 0067679 Nov 2000 WO
WO 0115650 Mar 2001 WO
WO 0117462 Mar 2001 WO
WO 03047468 Jun 2003 WO
WO 03084443 Oct 2003 WO
WO 2004019825 Mar 2004 WO
WO 2004021893 Mar 2004 WO
WO 2004023980 Mar 2004 WO
WO 2004030568 Apr 2004 WO
WO 2004030569 Apr 2004 WO
WO 2004030570 Apr 2004 WO
WO 2004032724 Apr 2004 WO
WO 2004032796 Apr 2004 WO
WO 2004037128 May 2004 WO
WO 2004037317 May 2004 WO
WO 2004039432 May 2004 WO
WO 2004043265 May 2004 WO
WO 2004043273 May 2004 WO
WO 2004043293 May 2004 WO
WO 2004045370 Jun 2004 WO
WO 2004045378 Jun 2004 WO
WO 2004045463 Jun 2004 WO
WO 2004047677 Jun 2004 WO
WO 2004060217 Jul 2004 WO
WO 2004060470 Jul 2004 WO
WO 2004062725 Jul 2004 WO
WO 2004066803 Aug 2004 WO
WO 2004066826 Aug 2004 WO
WO 2004069287 Aug 2004 WO
WO 2004075789 Sep 2004 WO
WO 2004080352 Sep 2004 WO
WO 2004082523 Sep 2004 WO
WO 2004082527 Sep 2004 WO
WO 2004082528 Sep 2004 WO
WO 2004082536 Sep 2004 WO
WO 2004082537 Sep 2004 WO
WO 2004082538 Sep 2004 WO
WO 2004082757 Sep 2004 WO
WO 2004084746 Oct 2004 WO
WO 2004084770 Oct 2004 WO
WO 2004089246 Oct 2004 WO
WO 2004089250 Oct 2004 WO
WO 2004089253 Oct 2004 WO
WO 2004091449 Oct 2004 WO
WO 2004091454 Oct 2004 WO
WO 2004093638 Nov 2004 WO
WO 2004093726 Nov 2004 WO
WO 2004093728 Nov 2004 WO
WO 2004093730 Nov 2004 WO
WO 2004093745 Nov 2004 WO
WO 2004093935 Nov 2004 WO
WO 2004096100 Nov 2004 WO
WO 2004103222 Dec 2004 WO
WO 2004103223 Dec 2004 WO
WO 2004105584 Dec 2004 WO
WO 2004105651 Dec 2004 WO
WO 2004112582 Dec 2004 WO
WO 2004112585 Dec 2004 WO
WO 2004112643 Dec 2004 WO
WO 2004112652 Dec 2004 WO
WO 2004112657 Dec 2004 WO
WO 2004112658 Dec 2004 WO
WO 2005000152 Jan 2005 WO
WO 2005002424 Jan 2005 WO
WO 2005002466 Jan 2005 WO
WO 2005004753 Jan 2005 WO
WO 2005007017 Jan 2005 WO
WO 2005007018 Jan 2005 WO
WO 2005007036 Jan 2005 WO
WO 2005007037 Jan 2005 WO
WO 2005009285 Feb 2005 WO
WO 2005009286 Feb 2005 WO
WO 2005009505 Feb 2005 WO
WO 2005009506 Feb 2005 WO
WO 2005011473 Feb 2005 WO
WO 2005011534 Feb 2005 WO
WO 2005011535 Feb 2005 WO
WO 2005013860 Feb 2005 WO
WO 2005018507 Mar 2005 WO
WO 2005021063 Mar 2005 WO
WO 2005023155 Mar 2005 WO
WO 2005025644 Mar 2005 WO
WO 2005027790 Mar 2005 WO
WO 2005027797 Mar 2005 WO
WO 2005034812 Apr 2005 WO
WO 2005039428 May 2005 WO
WO 2005039452 May 2005 WO
WO 2005046488 May 2005 WO
WO 2005046528 May 2005 WO
WO 2005046529 May 2005 WO
WO 2005046530 May 2005 WO
WO 2005046531 May 2005 WO
WO 2005048883 Jun 2005 WO
WO 2005049103 Jun 2005 WO
WO 2005051226 Jun 2005 WO
WO 2005055811 Jun 2005 WO
WO 2005055883 Jun 2005 WO
WO 2005058206 Jun 2005 WO
WO 2005065585 Jul 2005 WO
WO 2005065593 Jul 2005 WO
WO 2005065594 Jul 2005 WO
WO 2005070342 Aug 2005 WO
WO 2005070343 Aug 2005 WO
WO 2005072654 Aug 2005 WO
WO 2005072655 Aug 2005 WO
WO 2005079706 Sep 2005 WO
WO 2005082288 Sep 2005 WO
WO 2005082289 Sep 2005 WO
WO 2005084595 Sep 2005 WO
WO 2005087139 Sep 2005 WO
WO 2005087140 Sep 2005 WO
WO 2006000763 Jan 2006 WO
WO 2006000776 Jan 2006 WO
WO 2006002492 Jan 2006 WO
WO 2006004679 Jan 2006 WO
WO 2006005015 Jan 2006 WO
WO 2006009690 Jan 2006 WO
WO 2006011127 Feb 2006 WO
WO 2006012011 Feb 2006 WO
WO 2006012013 Feb 2006 WO
WO 2006012038 Feb 2006 WO
WO 2006012068 Feb 2006 WO
WO 2006012322 Feb 2006 WO
WO 2006019498 Feb 2006 WO
WO 2006026371 Mar 2006 WO
WO 2006026377 Mar 2006 WO
WO 2006026912 Mar 2006 WO
WO 2006027499 Mar 2006 WO
WO 2006028821 Mar 2006 WO
WO 2006029062 Mar 2006 WO
WO 2006031436 Mar 2006 WO
WO 2006031469 Mar 2006 WO
WO 2006032051 Mar 2006 WO
WO 2006034245 Mar 2006 WO
WO 2006035415 Apr 2006 WO
WO 2006041505 Apr 2006 WO
WO 2006044679 Apr 2006 WO
WO 2006048664 May 2006 WO
WO 2006050459 May 2006 WO
WO 2006050460 May 2006 WO
WO 2006054107 May 2006 WO
WO 2006054930 May 2006 WO
WO 2006055982 May 2006 WO
WO 2006060546 Jun 2006 WO
WO 2006063108 Jun 2006 WO
WO 2006063181 Jun 2006 WO
WO 2006063199 Jun 2006 WO
WO 2006064490 Jun 2006 WO
WO 2006065212 Jun 2006 WO
WO 2006065930 Jun 2006 WO
WO 2006066148 Jun 2006 WO
WO 2006066150 Jun 2006 WO
WO 2006069094 Jun 2006 WO
WO 2006070372 Jul 2006 WO
WO 2006073628 Jul 2006 WO
WO 2006076890 Jul 2006 WO
Related Publications (1)
Number Date Country
20050065594 A1 Mar 2005 US
Divisions (1)
Number Date Country
Parent 09425142 Oct 1999 US
Child 10191667 US
Continuations (2)
Number Date Country
Parent 10714034 Nov 2003 US
Child 10985534 US
Parent 10191667 Jul 2002 US
Child 10714034 US